Shots:

• The P-Ib study evaluates GLPG3667 (low/high dose) vs PBO in 31 patients in a ratio (1:1:1) in patients with moderate to severe plaque psoriasis for 4wks.
• Results: 40% of patients with the high dose of GLPG3667 showed improvement of 50% in PASI response from baseline @4wks. and was well tolerated with no serious AEs. 4 patients achieved a 52%- 65%- 74% and 81% improvement in PASI score- positive efficacy signals were also observed for other endpoints-
• The company plans to submit the results of GLPG3667 at scientific conferences for publication and in peer-reviewed medical journals. The company plans to initiate the P-IIb program of GLPG3667 for psoriasis in 2022

  Ref: Globe Newswire | Image: Nature